Information sur le cancer / Types de cancer / Cancer primitif inconnu / Traitement / Carcinome neuroendocrinien de siège primitif inconnu

Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, and Kundra V. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. (2012). European Radiology. Springer. 23:400-407 DOI 10.1007/s00330-012-2617-y.

Fizazi K, Greco FA, Pavlidis N, et al. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2011). Annals of Oncology. Oxford University Press. 22(Supplement 5): vi64-vi68 doi: 10.1093/annoc/mdr389.

Greco FA & Hainsworth JD. Cancer of unknown primary site. DeVita VT Jr, Lawrence TS, & Rosenberg SA. (2015). Cancer: Principles & Practice of Oncology. (10th Édition). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 113:1720-1737.

Hainsworth JD, Greco FA. Chemotherapy of carcinoma of unknown primary site. Perry MC, Doll DC, Freter CE. (2012). Perry's The Chemotherapy Source Book. (5th Édition). Lippincott Williams Wilkins. Chapter 37. Extrait de: http://www.lwwoncology.com.

Lisovsky M, Tafe LJ, Lefferts JA. Molecular diagnostics of metastatic malignancies. Tan D, Lynch, HT (eds.). (2013). Principles of Molecular Diagnostics and Personalized Cancer Medicine. Lippincott Williams & Wilkins. Chapter 42.

National Comprehensive Cancer Network. Occult Primary (Cancer of Unknown Primary [CUP]) (Version 3.2014). Retrieved on 7/7/2014. Extrait de: http://www.nccn.org/professionals/physician_gls/pdf/occult.pdf.